Luspatercept enhances hemoglobin levels in a Chinese boy with congenital sideroblastic anemia: A case report

Figure 1 18% of ringed sideroblasts within the erythroblasts in bone marrow of the patient. The orange arrow indicate the ringed sideroblast.

Figure 2 Changes in laboratory data in the patient after the administration of luspatercept. A: The median hemoglobin during the overall treatment with three doses of luspatercept was 90 (75-101) g/L. The blue arrows indicate the administration of luspatercept; B: The absolute value of reticulocytes in the patient after the administration of luspatercept. The median absolute reticulocyte count was 0.0593 (0.0277-0.1030) × 10¹²/L. The blue arrows indicate the administration of luspatercept; C: Changes in serum ferritin levels in the patient after the administration of luspatercept. The blue arrows indicate the administration of luspatercept. HGB: Hemoglobin; SF: Serum ferritin; ARC: Absolute reticulocyte count.